Drug updated on 11/16/2023

Dosage FormTablet (oral: 100 mg)
Drug ClassNon-nucleoside reverse transcriptase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg with no prior antiretroviral treatment history, or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.